Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.65 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656219 | 1.00 | CYP3A4 (0.77) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL29624424 | 1.00 | CYP3A4 (0.77) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL13680427 | 0.96 | CYP3A4 (0.75) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL6913489 | 0.91 | CYP3A4 (0.74) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL656428 | 0.90 | CYP1B1 (0.81) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL656427 | 0.90 | CYP1B1 (0.81) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL25221764 | 0.89 | CYP3A4 (0.76) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL15507014 | 0.89 | CYP3A4 (0.76) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL12158657 | 0.89 | CYP3A4 (0.62) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL11817525 | 0.87 | CYP3A4 (0.74) | CYP3A4PTPN1CYP1B1CYP1A2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732588-B | Organic compound, light-emitting element, and light-emitting device | 株式会社半导体能源研究所 | 2020-10-09 | — | — | CN | disclosed |
| US-10280156-B2 | Heteroaromatic chalcone derivatives and their medical use | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2019-05-07 | — | — | US | disclosed |
| US-9929352-B2 | Organic compound, light-emitting element, display module, lighting module, light-emitting device, display device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20170253583-A1 | HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE | Universität Wien (AT) | 2017-09-07 | — | — | US | disclosed |
| EP-3186237-A1 | HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE | Medizinische Universität Wien (AT) | 2017-07-05 | — | — | EP | disclosed |
| US-20160190471-A1 | Organic Compound, Light-Emitting Element, Display Module, Lighting Module, Light-Emitting Device, Display Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-06-30 | — | — | US | disclosed |
| WO-2016030510-A1 | HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2016-03-03 | — | — | WO | disclosed |
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8912186-B2 | Allosteric protein kinase modulators | UNIVERSITAET DES SAARLANDES (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP3A4 1380/4885PTPN1 875/4885CYP1B1 780/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP3A4 1236/4885PTPN1 837/4885CYP1B1 747/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP3A4 1407/4885PTPN1 963/4885CYP1B1 604/4885 |
| US-20160190471-A1 | Organic Compound, Light-Emitting Element, Display Module, Lighting Module, Light-Emitting Device, Display Device, Electronic Device, and Lighting Device | DPYD, P2RY6, NLRP1 | CYP3A4 556/4885PTPN1 2843/4885CYP1B1 615/4885 |
| US-20170253583-A1 | HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE | CYP2E1, CYP3A43, CYP11B1 | CYP3A4 33/4885PTPN1 670/4885CYP1B1 25/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP3A4 1407/4885PTPN1 963/4885CYP1B1 604/4885 |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | CYP3A4 4232/4885PTPN1 1145/4885CYP1B1 4714/4885 |
| US-10280156-B2 | Heteroaromatic chalcone derivatives and their medical use | CYP2E1, CYP3A43, CYP11B1 | CYP3A4 33/4885PTPN1 670/4885CYP1B1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.